Report of Foreign Issuer (6-k)
August 06 2018 - 6:46AM
Edgar (US Regulatory)
Securities
and Exchange Commission
w
ashington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of
|
August
|
|
2018
|
Commission File Number
|
001-36458
|
|
|
Neovasc
Inc.
|
(Translation of registrant’s name into English)
|
Suite 5138 - 13562 Maycrest Way
Richmond, British Columbia, Canada, V6V 2J7
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document
|
|
|
|
|
|
Document 1
|
|
News Release dated August 6, 2018 - Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology
|
|
|
|
DOCUMENT 1
Neovasc Announces Publication of Safety
and Efficacy Results from REDUCE Study in International Journal of Cardiology
NASDAQ, TSX: NVCN
VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc
Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally
invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy
of the Reducer: A multicenter clinical registry - REDUCE study" in the
International Journal of Cardiology
, which is
available online at: https://doi.org/10.1016/j.ijcard.2018.06.116.
In this published study, the safety and effectiveness
of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed for the treatment of refractory angina,
was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan, Tel Aviv and Antwerp. The
researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and reducing symptoms of angina pectoris
in 141 consecutive patients suffering from coronary artery disease and chronic refractory angina. The safety endpoint of the study
was to evaluate the rate of successful Reducer delivery and deployment in the absence of any device-related events.
The investigator demonstrated that treatment
with the Reducer was very safe and significantly reduced the severity of angina as measured by the Canadian Cardiovascular Society
classification ("CCS") (from a mean at baseline of 3.05±0.53 to 1.63±0.98 at follow-up (p<0.001). Overall,
results show that 81% of the patients experienced improvement in their angina severity by at least one CCS class, and 45% of the
patients became free of any limiting angina as they improved by 2 or more grades in their CCS class. All parameters of quality
of life as measured by the Seattle Angina Questionnaire improved significantly (p <0.001). These benefits translated into a
significant reduction in the mean number of anti-ischemic drugs prescribed (2.37± 0.97 vs 2.17±0.95; p= 0.003).
"The publication is another 'real-world,'
non-randomized study which demonstrates clinical results in an additional 141 enrolled patients, that are remarkably consistent
with the results of the COSIRA randomized sham-controlled clinical trial. This recent manuscript published in the International
Journal of Cardiology is a testament to the benefits of the Reducer as a safe device, which can provide substantial qualify of
life improvements in patients with refractory angina, who do not have other suitable treatment alternatives," stated Fred
Colen, Neovasc's President and Chief Executive Officer. "We are very pleased to have this data published in such a highly-regarded
journal."
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available
in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment
of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information,
visit: www.neovasc.com.
This news release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws
regarding the future performance and potential benefit of the Reducer and growth of the cardiovascular marketplace. Words and phrases
such as 'potential', "believes," "may", "not yet" and "will" and similar words or expressions,
are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made
by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments,
as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause
the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking
statements, including, without limitation, the substantial doubt about the Company's ability to continue as a going concern; risks
relating to the warrants (the "Warrants") and senior secured convertible notes (the "Notes") issued pursuant
to the November 2017 underwritten public offering and concurrent private placement (together, the "2017 Financings"),
resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for significant additional
future capital and the Company's ability to raise additional funding; risks relating to cashless exercise and adjustment provisions
in the Warrants and Notes issued pursuant to the 2017 Financings, which could make it more difficult and expensive for the Company
to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant
number of common shares of the Company; risks relating to the exercise of Warrants or conversion of Notes issued pursuant to the
2017 Financings, which may encourage short sales by third parties; risks relating to the possibility that the Company's common
shares may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, which could affect their market price and
liquidity; risks relating to the Company's common share price being volatile; risks relating to the influence of significant shareholders
of the Company over the Company's business operations and share price; risks relating to the Company's significant indebtedness,
and its effect on the Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual
property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result
in the payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual
property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may
be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated
with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances,
which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk
that one or more of the Company's competitors may develop more effective or more affordable products; risks relating to the Company's
ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability
to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability
to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new
legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs
of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry,
including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation
of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks
associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products
and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing
processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated
with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's
products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating
to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the
Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company
could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws
by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting
pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's
ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems
and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the
downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members
or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable
terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully
enter into fundamental transactions as defined in the Series C warrants issued pursuant to the 2017 Financings; anti-takeover provisions
in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's
shareholders; risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement
with other issuers; and other factors referenced in the Company's filings with Canadian and U.S. securities regulators. These risk
factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's
Annual Report on Form 20-F and in Management's Discussion and Analysis for the quarter ended March 31, 2018 (copies of which may
be obtained at www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any
forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information,
future events or otherwise, except as required by law.
View
original content:http://www.prnewswire.com/news-releases/neovasc-announces-publication-of-safety-and-efficacy-results-from-reduce-study-in-international-journal-of-cardiology-300692132.html
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/August2018/06/c2079.html
%CIK: 0001399708
For further information:
Chris Clark, Chief Financial Officer,
Neovasc Inc., 604-248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568, jeremy@lifesciadvisors.com
CO: Neovasc Inc.
CNW 07:30e 06-AUG-18
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Neovasc
Inc.
|
|
(Registrant)
|
Date:
|
|
August 6, 2018
|
|
By:
|
/s/
Chris Clark
|
|
Name: Chris Clark
Title: Chief Financial Officer
|
|
|
|
|
|
|
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Oct 2023 to Oct 2024